We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App




Antibody Cancer Marker Causes Tumors to Light Up

By MedImaging International staff writers
Posted on 25 Nov 2015
Print article
Image: Glioblastoma in a PET scanner with (left) and without (right) the YY146 marker (Photo courtesy of Weibo Cai, WISC).
Image: Glioblastoma in a PET scanner with (left) and without (right) the YY146 marker (Photo courtesy of Weibo Cai, WISC).
A novel marker attaches to a molecule on highly aggressive brain cancer, resulting in glioblastoma tumor tissue being easily identified in a positron emission tomography (PET) scanner.

Developed by researchers at the University of Wisconsin (WISC; Madison, USA) and the Third Military Medical University (Chongqing, China), the antibody created is specific to a unique protein, called CD146, that is present on the surface of glioblastoma multiforme cancer cells; the antibody was joined to a copper isotope to create a radio-labeled anti-CD146 antibody (YY146). The researchers then implanted a human glioblastoma sample into a mouse and injected the antibody-marker combination into its blood, waiting for it to spread through the body.

When the mouse was later placed into a PET scanner, the tumors with a high level of CD146 protein on the outside of their cells were easily identified. In comparison, signals from a genetically distinct variant of glioblastoma with low CD146 activity were much weaker. In their study, the researchers also explored the potential therapeutic effects of YY146 on cancer stem cell (CSC) and epithelial-to-mesenchymal (ETM) properties of glioblastoma cells, demonstrating that it can mitigate aggressive U87MG phenotypes.

The researchers also demonstrated that YY146 could be used to detect CD146 in cancer cell lines and human resected tumor tissues of multiple other origins, such as in gastric, ovarian, liver, and lung tissues. These findings, according to the researchers, indicate a broad applicability of the YY146 marker in solid tumors, including for diagnosis, stratification, and targeted therapy. The study was published on November 9, 2015, in Proceedings of the National Academy of Sciences of the United States of America (PNAS).

“Most methods generate antibodies that recognize short fragments of the target protein, whereas our antibody recognizes the target in the biologically active form. So the antibodies can be readily used in living subjects, such as the animal models in this study and potentially in patients,” said senior author associate professor of radiology Weibo Cai, PhD, of WISC. “If the technique proves out in further tests, it could be used to diagnose some strains of aggressive glioblastoma, and also to evaluate treatment progress or even to test potential drugs.”

Related Links:

University of Wisconsin
Third Military Medical University


Gold Member
Solid State Kv/Dose Multi-Sensor
AGMS-DM+
New
Portable Radiology System
DRAGON ELITE & CLASSIC
MRI System
uMR 588
Dose Area Product Meter
VacuDAP

Print article

Channels

Radiography

view channel
:	Image: The AI model could be a valuable adjunct to human radiologists in breast cancer diagnoses and risk prediction (Photo courtesy of 123RF)

AI Model Predicts 5-Year Breast Cancer Risk from Mammograms

Approximately 13% of U.S. women, or one in every eight, are predicted to develop invasive breast cancer over their lifetime, with 1 in 39 women (3%) succumbing to the illness, according to the American... Read more

General/Advanced Imaging

view channel
Image: The CIARTIC Move self-driving mobile C-arm has received FDA clearance (Photo courtesy of Siemens)

Self-Driving Mobile C-Arm Reduces Imaging Time during Surgery

Intraoperative imaging faces significant challenges due to staff shortages and the high demands placed on surgical teams in the operating room (OR). A common challenge during many OR procedures is the... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more

Industry News

view channel
Image: Samsung Medison CEO Mr. Yongkwan Kim and Bracco Imaging CEO Dr. Fulvio Renoldi Bracco endorsed a MoU agreement (Photo courtesy of Bracco Group)

Samsung and Bracco Enter Into New Diagnostic Ultrasound Technology Agreement

Samsung Medison (Seoul, South Korea) and Bracco Imaging (Milan, Italy) have entered into a Memorandum of Understanding (MoU) agreement to pioneer a new area for diagnostic ultrasound devices and contrast agents.... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.